MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Eli Lilly and Co.

Uždarymo kaina

SektoriusSveikatos priežiūra

802.67 -2.75

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

796.87

Max

824

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.8B

8.8B

Pardavimai

2.1B

14B

P/E

Sektoriaus vid.

70.41

63.778

Pelnas, tenkantis vienai akcijai

5.32

Dividendų pajamingumas

0.73

Pelno marža

65.172

Darbuotojai

47,000

EBITDA

1.2B

6.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+28.39% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.73%

2.39%

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-43B

742B

Ankstesnė atidarymo kaina

805.42

Ankstesnė uždarymo kaina

802.67

Naujienos nuotaikos

By Acuity

59%

41%

315 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Eli Lilly and Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-03-19 15:54; UTC

Svarbiausios naujienos

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-26 15:14; UTC

Svarbiausios naujienos

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

2025-02-26 14:30; UTC

Svarbiausios naujienos

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

2025-02-10 12:00; UTC

Svarbiausios naujienos

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2025-02-07 10:30; UTC

Svarbiausios naujienos

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025-02-06 16:16; UTC

Svarbiausios naujienos
Uždarbis

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

2025-02-06 14:56; UTC

Uždarbis

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

2025-02-06 14:32; UTC

Rinkos pokalbiai
Uždarbis

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

2025-02-06 13:18; UTC

Svarbiausios naujienos
Uždarbis

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

2025-02-06 12:24; UTC

Uždarbis

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

2025-02-06 12:01; UTC

Uždarbis

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

2025-02-06 11:49; UTC

Uždarbis

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

2025-02-06 11:48; UTC

Uždarbis

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

2025-02-06 11:47; UTC

Uždarbis

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

2025-02-06 11:46; UTC

Uždarbis

Eli Lilly 4Q Gross Margin 82.2% >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q Humalog Rev $619.9M >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly Sees FY Rev $58B-$61B >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q Net $4.41B >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q EPS $4.88 >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q Rev $13.53B >LLY

2025-02-06 11:45; UTC

Uždarbis

Eli Lilly 4Q Adj EPS $5.32 >LLY

Akcijų palyginimas

Kainos pokytis

Eli Lilly and Co. Prognozė

Kainos tikslas

By TipRanks

28.39% į viršų

12 mėnesių prognozė

Vidutinis 1,033.87 USD  28.39%

Aukščiausias 1,190 USD

Žemiausias 900 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Eli Lilly and Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

789.4 / 825.32Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

315 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.